Sanofi Completes $3.68-Billion Acquisition of Principia Biopharma

Published on: 

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi announced on Sept. 28, 2020 that it has completed its acquisition of Principia Biopharma, a late-stage biopharmaceutical company located in San Francisco, CA, for approximately $3.68 billion.

The acquisition, first announced in Aug. 17, 2020, will give Sanofi access to Principia’s Bruton tyrosine kinase (BTK) inhibitors to add to its portfolio of next-generation transformative treatments for autoimmune diseases. The BTKs include BTK inhibitor ‘168, currently in a Phase IIb study for multiple sclerosis; rilzabrutinib, an oral BTK inhibitor currently in a Phase III program for moderate to severe pemphigus; and PRN473 topical, a topical agent currently in Phase I trials for immune-mediated diseases.

Sanofi and Principia had previously formed a collaboration in 2017 under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases.

Advertisement

Source: Sanofi​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Related Content:

Top NewsMergers and AcquisitionsDeals, Development and Manufacturing
Novartis and Monte Rosa Therapeutics Form $2.1 Billion Global License Agreement for MGD-based Therapeutics
Merck Acquires Modifi Biosciences
Behind the Headlines: GLP-1 Shortage, Nobel Prize, RNA Editing, and More